Yuki Kageyama to Biomarkers, Tumor
This is a "connection" page, showing publications Yuki Kageyama has written about Biomarkers, Tumor.
Connection Strength
0.745
-
Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions. Hum Pathol. 2025 Jun; 160:105823.
Score: 0.514
-
Telomere length and telomerase activity in bladder and prostate cancer cell lines. Int J Urol. 1997 Jul; 4(4):407-10.
Score: 0.074
-
C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008 Apr; 101(8):978-81.
Score: 0.039
-
Increased expression of sialyl-Lewis A correlates with poor survival in upper urinary tract urothelial cancer patients. Anticancer Res. 2003 Jul-Aug; 23(4):3441-6.
Score: 0.028
-
Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 2021 02; 9(2).
Score: 0.024
-
Detection of disseminated urothelial cancer cells in peripheral venous blood by a cytokeratin 20-specific nested reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res. 1999 Jul; 90(7):753-7.
Score: 0.021
-
Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer. Int J Clin Oncol. 2016 Aug; 21(4):764-772.
Score: 0.017
-
[Result of treatment for advanced germ cell tumor in the last decade]. Nihon Hinyokika Gakkai Zasshi. 2010 Mar; 101(3):539-46.
Score: 0.011
-
Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: a report of three cases. Int J Urol. 2007 May; 14(5):455-7.
Score: 0.009
-
Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003 Nov 15; 9(15):5501-7.
Score: 0.007